Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2/3 Open-label Study to Evaluate the Safety, Tolerability and Efficacy of an Adeno-associated Virus Vector Containing an Expression Cassette of the Human Factor IX Transgene (BBM-H901) Injection in Patients With Hemophilia B

NCT05203679 is registered in ClinicalTrials.gov with Shanghai Xinzhi BioMed Co., Ltd. as lead sponsor.

NCT NCT05203679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05203679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2/3 Open-label Study to Evaluate the Safety, Tolerability and Efficacy of an Adeno-associated Virus Vector Containing an Expression Cassette of the Human Factor IX Transgene (BBM-H901) Injection in Patients With Hemophilia B
Lead sponsor
Shanghai Xinzhi BioMed Co., Ltd.
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
December 30, 2021
Completion date
June 30, 2028
Enrollment
32 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia b